Real-World Experience With Pacritinib in the US
Real-World Experience With Pacritinib in the US
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer
Managing Myelofibrosis-Associated Thrombocytopenia
Managing Myelofibrosis-Associated Thrombocytopenia
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 109/L?
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 109/L?
How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment
How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment
Improving Transfusion Independence With JAK Inhibitor Therapy
Improving Transfusion Independence With JAK Inhibitor Therapy
Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis
Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis
Pacritinib for Myelofibrosis Across the Cytopenic Spectrum
Pacritinib for Myelofibrosis Across the Cytopenic Spectrum
Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis
Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis
Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma
Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma
Advancements in GU Cancers: Key Data from AUA 2024
Advancements in GU Cancers: Key Data from AUA 2024
Case by Case: Optimizing Dual Immune Checkpoint Inhibitor Combination Therapies in Advanced Driver-Negative Non–Small Cell Lung Cancer
Case by Case: Optimizing Dual Immune Checkpoint Inhibitor Combination Therapies in Advanced Driver-Negative Non–Small Cell Lung Cancer
